Frank Schestag, PhD, Joins Proteintech as Commercial Director in Europe
Proteintech, the benchmark in antibodies and proteins, welcomes Frank Schestag, PhD, as Commercial Director. He will be providing leadership to the sales and marketing teams and growing the markets in Germany, Austria, and Switzerland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190710005684/en/
Dr. Schestag comes to Proteintech with 18 years of experience in sales and management of scientific reagents and equipment. At Fisher Scientific as Director of Sales and then promoted to Senior Sales Director of the Life Science Solution Group (Life Technologies), he led teams over 50 sales specialists in central Europe and responsible for over $200M in revenue. Throughout his career, Dr. Schestag has exceled in building teams, whether it be technical support, sales, logistics, or accounting. Besides high performance, his sites have consistently scored the highest in employee satisfaction and engagement.
“Europe has always been at the forefront of science. Frank’s experience in leadership will enable us to better serve Europe’s scientific community as well as the pharmaceutical and biomedical communities,” says Proteintech CEO Jason Li.
“I am very excited to become a member of the Proteintech Group. For me, it is a perfect fit to support Proteintech with the experience I have gained in the last 20 years in science, sales, operations, and the European market,” says new Proteintech Commercial Director, Dr. Frank Schestag, “I believe it will bring us more successes than we’re already seeing today.”
Dr. Schestag received his PhD in Biochemistry at the Christian-Albrechts-University in Kiel. Afterward, he began his career at Fermentas, a manufacturer of molecular biology products. He was responsible for developing the business in technical support, customer service, and commercial organization. As the Sales Director for Europe, he built up and led a direct sales team operating in 15 different European countries. In large part due to Dr. Schestag’s stewardship, Fermentas accelerated in growth and was acquired by Thermo Fisher, where he transitioned to General Manager and Site Leader. Through these experiences, Dr. Schestag has gained an intimate knowledge of the German market and how to drive growth there.
About Proteintech Group
Proteintech is an antibody manufacturer selling directly to scientists and only selling its own products to maintain the highest level of quality control leading to superior reproducibility and lot consistency. With over 2/3 of the human genome completed, we have a catalog of over 12,000 antibodies against 12,000 targets covering nearly all research areas. With its acquisition of Humanzyme, Proteintech now offers the Humankine® product line of animal-free human-cell expressed proteins. To view tens of thousands of publications and in-house validation images in WB, IHC, IF, FC, IP, CHIP, and KD/KO siRNA experiments using our antibodies and to learn more about Proteintech and their mission to deliver products directly from their bench to the researcher’s bench, please visit www.ptglab.com
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ADVA14.10.2019 18:02:06 CEST | Press release
ADVA recognized as a Leaders Board Partner in the Intel® Network Builders’ Program
CA-VERIMATRIX14.10.2019 17:42:05 CEST | Press release
Ksmartech, Leading Korean Developer Partners with Verimatrix to Offer Powerful App Security Technology for Automotive, Financial Markets
SERVIER14.10.2019 14:02:08 CEST | Press release
Analysis of Patients With Prior Gastrectomy Treated With LONSURF® (trifluridine/tipiracil) Published in JAMA Oncology
ISL14.10.2019 12:51:06 CEST | Press release
‘Energy’ Pulses Through Superstar Swimmers in International Swimming League Leg in Naples
LIBELIUM14.10.2019 12:42:06 CEST | Press release
Libelium Focuses Its Business on Professional IoT Technology Closing the Electronics Maker Division "Cooking Hacks"
CA-SOTIO14.10.2019 12:10:03 CEST | Press release
PPF and SOTIO Invest $6.5 Million in MaveriX Oncology and its Lead Program MVX-5005
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom